Brief: Pharmather Holdings Bags FDA's Orphan Drug Tag For Drug Treating Rett Syndrome
02/02/2023 12:46
Feb 2 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER HOLDINGS ANNOUNCES FDA GRANT OF ORPHAN DRUG
DESIGNATION TO KETARX™ (KETAMINE) FOR THE TREATMENT OF RETT
SYNDROME
Source text for Eikon: ID:nGNX292Bc9
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application